- Home
- KNSA
as 10-22-2024 4:00pm EST
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab.
Upcoming Earnings Alert:
Get ready for potential market movements as Kiniksa Pharmaceuticals Ltd. KNSA prepares to release earnings report on 29 Oct 2024.
| Founded: | 2015 | Country: | United Kingdom |
| Employees: | N/A | City: | LONDON |
| Market Cap: | 1.7B | IPO Year: | 2018 |
| Target Price: | $33.60 | AVG Volume (30 days): | 283.3K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.15 | EPS Growth: | N/A |
| 52 Week Low/High: | $14.12 - $27.92 | Next Earning Date: | 10-29-2024 |
| Revenue: | $338,930,000 | Revenue Growth: | 20.69% |
| Revenue Growth (this year): | 58.95% | Revenue Growth (next year): | 36.22% |
Stock Insider Trading Activity of Kiniksa Pharmaceuticals Ltd. (KNSA)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Paolini John F. | KNSA | CHIEF MEDICAL OFFICER | Sep 1 '24 | Sell | $26.61 | 60,692 | $1,584,991.40 | 53,516 | |
| Tessari Eben | KNSA | CHIEF OPERATING OFFICER | Aug 27 '24 | Sell | $26.91 | 17,500 | $470,925.00 | 119,911 |
Latest Kiniksa Pharmaceuticals Ltd. News
KNSA Breaking Stock News: Dive into KNSA Ticker-Specific Updates for Smart Investing
GlobeNewswire
14 hours ago
Kiniksa Pharmaceuticals to Report Third Quarter 2024 Financial Results on October 29, 2024
Simply Wall St.
8 days ago
High Growth Tech Stocks To Watch In October 2024
Zacks
14 days ago
Wall Street Analysts Think Kiniksa Pharmaceuticals (KNSA) Could Surge 42.34%: Read This Before Placing a Bet
GuruFocus.com
14 days ago
Baker Bros. Advisors LP Increases Stake in Kiniksa Pharmaceuticals
GlobeNewswire
22 days ago
NHL Hall-of-Famer, Henrik Lundqvist, Teams Up with Kiniksa Pharmaceuticals to Launch Life DisRPted™ Campaign to Drive Awareness of Recurrent Pericarditis
MT Newswires
a month ago
Kiniksa Pharmaceuticals International Insider Sold Shares Worth $437,325, According to a Recent SEC Filing
Simply Wall St.
a month ago
Top High Growth Tech Stocks To Watch In September 2024
MT Newswires
a month ago
Jefferies Initiates Kiniksa Pharmaceuticals at Buy With $40 Price Target
Compare KNSA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "KNSA Kiniksa Pharmaceuticals Ltd. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.